WELCOME TO The HEALTHCARE REPORT
Outpatient Imaging Affiliates
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Managed Healthcare Executive | February 06, 2020
The top healthcare technologies for 2020 aren’t new, but they are on the cusp of moving into broader use. In a sign of the growing maturity of some of these technologies such as machine learning, voice recognition, and natural language processing vendors are combining them to build solutions that solve real-world problems for providers and insurers. That’s because the focus of digitally enabled healthcare “is less about the technologies to be used and more about doing things di...
HIT Consultant | February 10, 2020
CitiusTech, a leading provider of healthcare technology services and solutions, today announced a partnership with Google Cloud to accelerate digital transformation and cloud adoption across healthcare organizations. As a Google Cloud partner, CitiusTech will enable medical technology companies, providers, payers, and life sciences organizations to modernize their mission-critical IT by integrating digital solutions on Google Cloud Platform (GCP). CitiusTech now has a practice focused on GCP tha...
Alira Health | January 31, 2022
Alira Health, a global healthcare consulting and technology firm, announced that it has acquired Self Care Catalysts, Inc., a digital health company headquartered in Toronto, Canada. Self Care Catalysts focuses on patients and puts them at the center of human networks, technology, and science. Self Care Catalysts’ digital health platform, Health Storylines™, helps patients gain an intimate understanding of their health journey while managing their conditions and generating clinica...
FUTURE OF HEALTHCARE
Medicago | May 06, 2022
Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills.
COVIFENZ® is indicated for active immunizatio...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE